Royalty Pharma plc
Royalty Pharma buys biopharmaceutical royalties and funds innovations in the US. It acquires and evaluates royalties on various therapies. The company collaborates with innovators from academia, research hospitals, and industry companies. Its portfolio includes royalties on 35 commercial products and 14 development-stage candidates across various therapeutic areas. Founded in 1996, Royalty Pharma is based in New York City.
Overview
Strengths
- With an appreciation Potential of 218.70%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (19.68) is lower than the sector mean (91.15).
- Price to book ratio (2.43) is lower than the sector mean (24.44).
- The company has high returns. ROIC (19.02%) is higher than the sector mean (6.02%).
- EV/EBIT (15.16) is lower than the sector mean.
- Price to free cash flow (6.11) is lower than the sector mean.
- Strong EBITDA Margin of 60.43%.
Weaknesses
- The company has high debt. Net Debt to EBITDA Ratio (4.89) is higher than the sector mean.
Key Financial Data
| Indicator | Value |
|---|
| PER | 19.3 |
| EV/EBITDA | 17.0 |
| Price/Free Cash Flow' | 6.0 |
| ROIC | 19.0% |
| Net Debt/EBITDA | 4.9 |